Braveheart Inv Regulatory News (BRH)

This announcement contains inside information as stipulated under the Market Abuse Regulation (EU) No. 596/2014 and is in accordance with the Company's obligations under Article 17 of that Regulation. Upon the publication of this announcement, the inside information is considered to be in the public domain.

18 September 2019

Braveheart Investment Group plc

("Braveheart" or the "Company")

Discussions to purchase the remaining share capital of Paraytec Limited

Braveheart Investment Group plc (AIM: BRH), the fund management and strategic investor Group, announces that Braveheart has made a private offer to the shareholders of Paraytec Limited ("Paraytec") to acquire the remaining issued share capital of Paraytec not currently owned by Braveheart (the "Offer"). If the shareholders of Paraytec accept the Offer, Braveheart will own the entire issued share capital of Paraytec.

Based on full acceptance of the Offer, it will be satisfied by the issue to Paraytec shareholders of 995,191 new ordinary shares in Braveheart (the "Consideration Shares"). The Consideration Shares have an aggregate value of £111,652, based on the volume weighted average price of a Braveheart ordinary share calculated for the period 1 July 2019 to 31 August 2019. If issued, the Consideration Shares will rank pari passu in all respects with the Company's existing ordinary shares. Application will be made to the London Stock Exchange for admission to trading on the AIM market for any Consideration Shares issued.

In accordance with Article 12 of the Articles of Association of Paraytec, accepting shareholders will also be required to approve a Drag-Along Right. If more than 75 per cent., but less than 100 per cent., of the holders of each ordinary share agree to sell their shares, the Drag-Along Right will be used to require all remaining shareholders to sell their shares at the same price.

The Offer is open for acceptance by shareholders of Paraytec until 5pm on Monday 30 September 2019, after which the Offer will lapse.

Paraytec develops high performance specialist detectors for the analytical and life sciences instrumentation market. Based in York, Paraytec has developed and patented its innovative ActiPix™ technology for optical imaging and absorbance measurements of fluid samples flowing in capillaries or fluid flow cuvettes. Braveheart currently owns 56 per cent. of the issued share capital of Paraytec.

A further announcement will be made in due course.

For further information: